Table. 5.

Results of proficiency testing for therapeutic drug monitoring of immunosuppressants subgroup test substances during 2019

Test substances Method 19-01 19-02 19-03 19-04




No. of labs Mean±SD CV (%) No. of labs Mean±SD CV (%) No. of labs Mean±SD CV (%) No. of labs Mean±SD CV (%)
Cyclosporine All methods 50 54.07±7.06 13.06 50 188.85±16.04 8.49 52 176.30±19.98 11.34 52 47.81±7.34 15.35
Architect i 29 55.77±7.42 13.30 29 194.96±12.59 6.46 28 180.40±17.58 9.74 28 49.14±6.74 13.71
LC-MS/MS 7 53.53±4.56 8.51 7 191.77±18.10 9.44 8 187.83±9.47 5.04 8 52.16±3.29 6.31
Cobas e411/e601/e602/e801 4 45.83±5.32 11.60 4 164.70±2.31 1.40 6 149.33±16.81 11.26 6 38.93±7.29 18.73
Dimension 6 50.86±2.44 4.79 6 183.78±1.99 1.08 6 183.83±5.86 3.19 6 49.12±3.57 7.27
Everolimus All methods (LC-MS/MS) 11 0.03±0.10 300.00 11 3.23±0.31 9.69 12 3.01±0.18 6.03 12 0.09±0.17 184.81
Sirolimus All methods 14 3.08±0.32 10.41 14 7.92±1.73 21.83 15 8.53±1.50 17.64 15 3.77±0.39 10.38
LC-MS/MS 10 2.94±0.54 18.30 10 6.76±0.35 5.19 11 7.73±0.62 8.06 11 3.73±0.45 12.12
Architect i 4 3.20±0.00 0.00 4 10.40±0.50 4.78 4 11.07±0.15 1.38 4 3.90±0.00 0.00
Tacrolimus (FK506) All methods 72 4.06±0.35 8.73 72 9.29±0.64 6.90 73 9.01±0.64 7.14 73 3.95±0.37 9.47
Architect i 48 3.99±0.28 7.08 48 9.33±0.41 4.38 47 8.91±0.43 4.78 47 3.85±0.24 6.27
Dimension 9 5.01±0.39 7.72 9 10.36±0.40 3.82 10 9.90±0.49 4.95 10 4.60±0.34 7.39
Cobas e411/e601/e602/e801 8 3.71±0.63 16.88 8 8.66±0.61 7.06 9 8.59±0.61 7.09 9 3.92±0.37 9.52
LC-MS/MS 6 4.07±0.33 8.03 6 8.92±0.60 6.71 7 8.54±0.37 4.32 7 3.95±0.23 5.94

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) instruments with various manufacturers are combined. The instruments were from the following companies: Architect i, Instruments of Cobas e modules, and Dimension (Abbott Laboratories, Chicago, IL, USA), Roche Diagnostics (Mannheim, Germany), and Siemens Healthineers (Erlangen, Germany).

Abbreviations: SD, standard deviation; CV, coefficients of variation.

J Lab Med Qual Assur 2020;42:183~193 https://doi.org/10.15263/jlmqa.2020.42.4.183
© Lab Med Qual Assur